Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Common Equity (2016 - 2025)

Arrowhead Pharmaceuticals' Common Equity history spans 16 years, with the latest figure at $568.4 million for Q4 2025.

  • For Q4 2025, Common Equity rose 913.68% year-over-year to $568.4 million; the TTM value through Dec 2025 reached $568.4 million, up 913.68%, while the annual FY2025 figure was $503.4 million, 163.48% up from the prior year.
  • Common Equity reached $568.4 million in Q4 2025 per ARWR's latest filing, up from $503.4 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $684.2 million in Q1 2025 to a low of $56.1 million in Q4 2024.
  • Average Common Equity over 5 years is $403.6 million, with a median of $427.6 million recorded in 2021.
  • Peak YoY movement for Common Equity: tumbled 67.72% in 2024, then surged 913.68% in 2025.
  • A 5-year view of Common Equity shows it stood at $372.6 million in 2021, then increased by 6.39% to $396.4 million in 2022, then crashed by 56.17% to $173.7 million in 2023, then crashed by 67.72% to $56.1 million in 2024, then soared by 913.68% to $568.4 million in 2025.
  • Per Business Quant, the three most recent readings for ARWR's Common Equity are $568.4 million (Q4 2025), $503.4 million (Q3 2025), and $522.3 million (Q2 2025).